Article
Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor-Mutated Nonsquamous Non-Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study.
JMIR cancer - 3 Mar 2025
Aye Phyu Sin, Barnes Joanne, Laking George, Cameron Laird, Anderson Malcolm, Luey Brendan, Delany Stephen, Harris Dean, McLaren Blair, Brenman Elliott, Wong Jayden, Lawrenson Ross, Arendse Michael, Tin Tin Sandar, Elwood Mark, Hope Philip, McKeage Mark James
Abstract excerpt
Background: Health care system-wide outcomes from routine treatment with erlotinib and gefitinib are incompletely understood. Objective: The aim of the study is to describe the effectiveness of erlotinib and gefitinib during the first decade of their routine use for treating advanced epidermal growth factor receptor (EGFR) mutation-positive nonsquamous non-small cell lung cancer in the entire cohort of patients...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Gefitinib
- Erlotinib Hydrochloride